Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
125 studies found for:    "Leishmaniasis"
Show Display Options
Rank Status Study
1 Completed Clinical Trial of Miltefosine to Treat Mucosal Leishmaniasis
Conditions: Leishmaniasis;   Leishmaniasis, Mucocutaneous
Interventions: Drug: Miltefosine;   Drug: Standard Treatment Meglumine antimoniate
2 Recruiting Low Antimonial Dosage in American Mucosal Leishmaniasis
Conditions: Mucosal Leishmaniasis;   Mucocutaneous Leishmaniasis
Intervention: Drug: Meglumine antimoniate
3 Completed Miltefosine to Treat Mucocutaneous Leishmaniasis
Conditions: Mucosal Leishmaniasis;   Cutaneous Leishmaniasis
Intervention: Drug: miltefosine
4 Completed Intralesional Antimony for Bolivian Cutaneous Leishmaniasis
Conditions: Leishmaniasis;   Cutaneous Leishmaniasis
Interventions: Drug: pentavalent antimony;   Procedure: cryotherapy;   Drug: placebo cream
5 Available Compassionate Use of Sodium Stibogluconate (Pentostam) for Cutaneous and Mucocutaneous New World Leishmaniasis
Conditions: Leishmaniasis, Cutaneous;   Leishmaniasis, Mucocutaneous
Intervention: Drug: sodium stibogluconate (Pentostam)
6 Recruiting The Association of Miltefosine and Pentoxifylline to Treat Mucosal Leishmaniasis: A Clinical Trial in Brazil
Condition: Leishmaniasis
Interventions: Drug: Meglumine antimoniate;   Drug: Miltefosine;   Drug: Pentoxifylline
7 Completed A Study Evaluating Sitamaquine Compared With Amphotericin B In The Treatment Of Visceral Leishmaniasis.
Conditions: Visceral Leishmaniasis;   Leishmaniasis, Visceral
Intervention: Drug: sitamaquine
8 Completed Study to Evaluate the Leish-111F + MPL-SE Vaccine in the Treatment of Mucosal Leishmaniasis
Condition: Leishmaniasis, Mucocutaneous
Intervention: Biological: Leish-111f + MPL-SE vaccine
9 Not yet recruiting Dedicated QT Study in Bolivian Patients Taking Impavido® (Miltefosine) for Mucocutaneous Leishmaniasis
Condition: Mucocutaneous Leishmaniasis
Intervention: Drug: Miltefosine
10 Not yet recruiting Spermiogram Assessment in Bolivian Patients Taking Impavido® (Miltefosine) for Mucocutaneous Leishmaniasis
Condition: Mucocutaneous Leishmaniasis
Intervention: Drug: Miltefosine
11 Completed Visceral Leishmaniasis and Malnutrition in Amhara Regional State, Ethiopia
Conditions: Visceral Leishmaniasis;   Malnutrition
12 Completed Oral Miltefosine Plus Topical Imiquimod to Treat Cutaneous Leishmaniasis
Condition: Cutaneous Leishmaniasis
Interventions: Drug: Miltefosine + Imiquimod;   Drug: Miltefosine 150 mg x day + Placebo
13 Completed Amphotericin B Treatment in Visceral Leishmaniasis
Condition: Visceral Leishmaniasis
Intervention: Drug: Amphotericin B deoxycholate given as daily administration
14 Completed Allopurinol, Glucantime, or Allopurinol/Glucantime for Cutaneous Leishmaniasis in Brazil
Condition: Leishmaniasis
Interventions: Drug: allopurinol;   Drug: glucantime
15 Completed Surveillance for Leishmaniasis Skin Lesions in Mali
Condition: Cutaneous Leishmaniasis
16 Completed A Community Trial for Visceral Leishmaniasis (VL)
Condition: Visceral Leishmaniasis
Interventions: Drug: Albendazole, Iron, Zinc and Vitamin A;   Other: Placebo
17 Completed Miltefosine to Treat Cutaneous Leishmaniasis in Bolivia
Condition: Cutaneous Leishmaniasis
Interventions: Drug: miltefosine;   Drug: antimony
18 Completed Phase 3 Study of Walter Reed (WR) 279,396 and Paromomycin Alone for the Treatment of Cutaneous Leishmaniasis in Panama
Condition: Cutaneous Leishmaniasis
Interventions: Drug: WR 279,396;   Drug: Paromomycin
19 Withdrawn SCH708980 With and Without AmBisome for Visceral Leishmaniasis
Conditions: Leishmaniasis;   Effects of Immunotherapy
Interventions: Drug: SCH708980 Anti-IL-10 monoclonal;   Drug: AmBisome
20 Completed An Effectiveness Study of Paromomycin IM Injection (PMIM) for the Treatment of Visceral Leishmaniasis (VL) in Bangladesh
Condition: Visceral Leishmaniasis
Intervention: Drug: Paromomycin sulfate

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years